Literature DB >> 14582454

Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.

Akira Miyazaki1, Masakazu Sakai, Yuichiro Sakamoto, Seikoh Horiuchi.   

Abstract

Acyl-coenzyme A:cholesterol acyltransferase (ACAT; Sterol O-acyltransferase/SOAT) is an intracellular enzyme that catalyzes the formation of cholesteryl esters from cholesterol and fatty acyl-coenzyme A. ACAT inhibitors reduce plasma cholesterol levels by suppressing absorption of dietary cholesterol and by suppressing the assembly and secretion of apolipoprotein B-containing lipoproteins such as very low density lipoprotein in liver and chylomicron in intestine. Moreover, ACAT inhibitors prevent the conversion of macrophages into foam cells in the arterial walls. Thus, ACAT inhibitors are under investigation for controlling hypercholesterolemia and the development of atherosclerosis. Some potent ACAT inhibitors have been tested for their efficacy and safety in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582454

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  7 in total

Review 1.  Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.

Authors:  Carlos Leon; John S Hill; Kishor M Wasan
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

2.  Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.

Authors:  Courtney Netherland; Douglas P Thewke
Journal:  Biochem Biophys Res Commun       Date:  2010-07-06       Impact factor: 3.575

3.  Extra-hepatic metabolism of 7-ketocholesterol occurs by esterification to fatty acids via cPLA2α and SOAT1 followed by selective efflux to HDL.

Authors:  Jung Wha Lee; Jiahn-Dar Huang; Ignacio R Rodriguez
Journal:  Biochim Biophys Acta       Date:  2015-01-22

4.  Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.

Authors:  Xiaoyue Pan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors.

Authors:  Douglas Thewke; Natalie Freeman-Anderson; Theresa Pickle; Courtney Netherland; Courtney Chilton
Journal:  Biochem Biophys Res Commun       Date:  2009-02-11       Impact factor: 3.575

6.  Sex-specific association of ACAT-1 rs1044925 SNP and serum lipid levels in the hypercholesterolemic subjects.

Authors:  Dong-Feng Wu; Rui-Xing Yin; Lynn Htet Htet Aung; Qing Li; Ting-Ting Yan; Xiao-Na Zeng; Ke-Ke Huang; Ping Huang; Jin-Zhen Wu; Shang-Ling Pan
Journal:  Lipids Health Dis       Date:  2012-01-13       Impact factor: 3.876

7.  LDL Promotes Disorders in β-Cell Cholesterol Metabolism, Implications on Insulin Cellular Communication Mediated by EVs.

Authors:  Lizbeth Guevara-Olaya; Brenda Chimal-Vega; César Yahel Castañeda-Sánchez; Leslie Y López-Cossio; Angel Pulido-Capiz; Octavio Galindo-Hernández; Raúl Díaz-Molina; Josefina Ruiz Esparza-Cisneros; Victor García-González
Journal:  Metabolites       Date:  2022-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.